bicalutamide


Also found in: Wikipedia.

bicalutamide

 [bi″kah-loo´tah-mīd]
an androgen antagonist used as an adjunct, in combination with a luteinizing hormone–releasing hormone analogue, in treatment of prostatic carcinoma; administered orally.

bicalutamide

Apo-Bicalutamide (CA), Casodex, Dom-Bicalutamide (CA), Gen-Bicalutamide (CA), Novo-Bicalutamide (CA), PHL-Bicalutamide (CA), PMS-Bicalutamide (CA), Ratio-Bicalutamide (CA), Sandoz Bicalutamide (CA)

Pharmacologic class: Nonsteroidal antiandrogen

Therapeutic class: Antineoplastic

Pregnancy risk category X

Action

Antagonizes effects of androgen at cellular level by binding to androgen receptors on target tissues

Availability

Tablets: 50 mg

Indications and dosages

Metastatic prostate cancer

Adults: 50 mg P.O. once daily

Contraindications

• Hypersensitivity to drug

• Women who are or may become pregnant

Precautions

Use cautiously in:

• previous hypersensitivity or serious adverse reaction to flutamide or nilutamide

• moderate to severe hepatic impairment

• children.

Administration

• Know that drug is given in combination with luteinizing hormone-releasing hormone (LHRH).

• Administer at same time each day.

Adverse reactions

CNS: headache, weakness, dizziness, depression, hypertonia, paresthesia, lethargy

CV: chest pain, peripheral edema, vasodilation, hypertension, thromboembolic disease

EENT: pharyngitis, bronchitis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, anorexia, dry mouth

GU: urinary tract infection, impotence

Musculoskeletal: bone and back pain

Respiratory: dyspnea, cough

Skin: rash, alopecia

Other: food distaste, weight gain, edema, pain, hot flashes, flulike symptoms

Interactions

Drug-drug. Warfarin: increased bicalutamide effects

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, cholesterol, BUN, creatinine: increased levels

Hemoglobin, white blood cells: decreased values

Patient monitoring

• Monitor prostate-significant antigen levels, CBC, and liver and kidney function test results.

• If patient is receiving warfarin concurrently, evaluate prothrombin time and International Normalized Ratio.

Patient teaching

• Instruct patient to take drug at same time each day, along with prescribed LHRH analog.

• Tell patient that any drug-related hair loss should reverse once therapy ends.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

bicalutamide

An oral non-steroidal antiandrogenic used to manage prostate cancer and hirsutism.

Adverse effects
Breast tenderness, gynaecomastia, hot flushes, gastrointestinal disorders, diarrhoea, nausea, elevated transaminases, jaundice, asthenia, pruritus.

bicalutamide

An anti-androgen, antineoplastic drug used in the treatment of advanced prostate cancer. A brand name is Casodex.
References in periodicals archive ?
The ENZAMET trial evaluated XTANDI plus ADT versus ADT plus a standard nonsteroidal antiandrogen therapy (bicalutamide, nilutamide or flutamide) in men with mHSPC to provide an active control.
In the bicalutamide-controlled study of chemotherapy-naive mCRPC patients, Grade 3-4 adverse reactions were reported in 39% of XTANDI patients and 38% of bicalutamide patients.
--Steroidal olmayan veya saf, ornegin; nilutamide, flutamide ve bicalutamide.
Therapeutic targeted agents such as Bicalutamide, an anti-androgen can be used against AR in AR expressing TNBC.
Medical management previously attempted included sertraline and bicalutamide, while surgical procedures included distal shunt and subsequent angioembolization of the left cavernosal artery.
we determine that Petitioner has shown by a preponderance of the evidence that all claims of the '438 patent for which trial was instituted, namely, claims 1-20, are unpatentable." The '438 patent describes administration of a therapeutically effective amount of a CYP17 inhibitor, such as abiraterone acetate, with a therapeutically effective amount of at least one additional therapeutic agent including, but not limited to, an anti-cancer agent, such as mitoxantrone, paclitaxel, docetaxel, leuprolide, goserelin, triptorelin, seocalcitol, bicalutamide, or flutamide, or a steroid, such as hydrocortisone, prednisone, or dexamethasone, the ruling states.
Kudarha, "Design, optimization and in-vitro study of folic acid conjugated-chitosan functionalized PLGA nanoparticle for delivery of bicalutamide in prostate cancer," Powder Technology, vol.
This group has been given luteinizing hormone-releasing hormone (LHRH) analogues for at least 6 months in combination with bicalutamide. A second control group (group 2) consisted of 38 men treated with ADT, without any local therapy until there was progression and were submitted to intervention only if local symptoms were present.
Home medications included acetaminophen, amlodipine, bicalutamide, docusate-senna, lidocaine patches, ondansetron, and polyethylene glycol.
Based on these findings, the patient was diagnosed with metastatic prostate cancer (cT3aN1M1b) and treated without prostate needle biopsy, with primary androgen deprivation therapy (ADT), including a GnRH antagonist (degarelix) and anti-androgen agent (bicalutamide).
Hormone therapy (aromatase inhibitors such as anastrozole, letrozole and exemestane, LHRH analogs, bicalutamide, and abiraterone) and chemotherapies can induce a greater bone resorption compared to its synthesis, creating a net effect of loss of bone mass, a reduction of resistance and a consequent increase in bone fractures in both women and men, even in the absence of trauma.
For men with prostate cancer receiving palliative therapies including non-steroidal antiandrogens (bicalutamide, flutamide and nilutamide), gynaecomastia with or without mastalgia is a common problem, affecting up to 79% of patients (4).